After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of DAPT treatment has been given.(Evidence: Level B，Recommendation: Class I)

In patients with a recent PCI scheduled for NCS, it is recommended that management of antiplatelet therapy is discussed between the surgeon, anaesthesiologist, and cardiologist.(Evidence: Level C，Recommendation: Class Ⅰ)

In high-risk patients with a recent PCI (e.g. STEMI patients or high-risk NSTE-ACS patients), a DAPT duration of at least 3 months should be considered before time-sensitive NCS.(Evidence: Level C，Recommendation: Class IIa)

In patients with a previous PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows.(Evidence: Level B，Recommendation: Class I)

If interruption of P2Y12 inhibitor is indicated, it is recommended to withhold ticagrelor for 3–5 days, clopidogrel for 5 days, and prasugrel for 7 days prior to NCS.(Evidence: Level B，Recommendation: Class I)

For patients undergoing high bleeding risk surgery (e.g. intracranial, spinal neurosurgery, or vitreoretinal eye surgery), it is recommended to interrupt aspirin for at least 7 days pre-operatively.(Evidence: Level C，Recommendation: Class Ⅰ)

In patients without a history of PCI, interruption of aspirin at least 3 days before NCS may be considered if the bleeding risk outweighs the ischaemic risk, to reduce the risk of bleeding.(Evidence: Level B，Recommendation: Class IIb)

In all patients scheduled for NCS, an accurate history and clinical examination are recommended.(Evidence: Level C，Recommendation: Class Ⅰ)

It is recommended to perform a pre-operative risk assessment, ideally at the same time as the NCS is proposed.(Evidence: Level B，Recommendation: Class I)

If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS.(Evidence: Level C，Recommendation: Class Ⅰ)